Search Results - "Mykulowycz, K"

A phase II trial of gemcitabine, irinotecan and panitumumab in advanced cholangiocarcinoma by Sohal, D.P.S., Mykulowycz, K., Uehara, T., Teitelbaum, U.R., Damjanov, N., Giantonio, B.J., Carberry, M., Wissel, P., Jacobs-Small, M., O'Dwyer, P.J., Sepulveda, A., Sun, W.

“…Current data suggest that chemotherapy combinations may be superior to single agents in biliary tract cancer. The epidermal growth factor receptor (EGFR)…”
Get full text

Phase I and pharmacological study of pazopanib in combination with oral topotecan in patients with advanced solid tumours by Kerklaan, B Milojkovic, Lolkema, M P J, Devriese, L A, Voest, E E, Nol-Boekel, A, Mergui-Roelvink, M, Langenberg, M, Mykulowycz, K, Stoebenau, J, Lane, S, Legenne, P, Wissel, P, Smith, D A, Giantonio, B J, Schellens, J H M, Witteveen, P O

“…Background: This phase I study evaluated the safety, tolerability, maximum tolerated dose (MTD) and pharmacokinetics of two dosing schedules of oral topotecan…”
Get full text

Panitumumab, gemcitabine, and irinotecan in patients with advanced or metastatic cholangiocarcinoma: A phase II study by Sun, W., Mykulowycz, K., Teitelbaum, U. R., Damjanov, N., Haller, D. G., Giantonio, B. J., Carberry, M., O'Dwyer, P. J.

“…Abstract only…”
Get full text

Combination of capecitabine, oxaliplatin with bevacizumab in treatment of advanced hepatocellular carcinoma (HCC): A phase II study by Sun, W., Haller, D. G., Mykulowycz, K., Rosen, M., Soulen, M., Capparo, M., Faust, T., Giantonia, B., Olthoff, K.

“…Abstract only 4574 Background: Hepatocellular carcinoma (HCC) is one of the most common cancers globally and its incidence of in USA is increasing…”
Get full text

A phase II trial of combination of capecitabine, oxaliplatin with bevacizumab in treatment of advanced hepatocellular carcinoma (HCC): Preliminary safety analysis by Hewitt, M. R., Sun, W., Haller, D. G., Mykulowycz, K., Tuite, C. M., Rosen, M. A., Soulen, M. C., Caparro, M., Giantonio, B. J., Olthoff, K. M.

“…Abstract only 14098 Background: Hepatocellular carcinoma (HCC) is the fifth most common cancer in the world and the third leading cause of cancer-related…”
Get full text